Business Context and Reporting Period
Lifecore Biomedical, Inc. (LFCR) filed a Form 8-K on April 10, 2025, reporting the results of a Special Meeting of Stockholders held on the same date. The meeting addressed compliance with Nasdaq Listing Rule 5635(d) regarding the issuance of common stock underlying Series A Convertible Preferred Stock.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Consequently, revenue, profit, cash flow, margins, debt, and liquidity metrics are not provided in this document.
Material Changes
The filing details the outcome of two stockholder proposals:
- Issuance Proposal: Stockholders approved the issuance of common stock underlying Series A Preferred Stock in an amount exceeding 19.99% of the shares outstanding prior to the issuance. This approval was required to comply with Nasdaq listing rules.
- Adjournment Proposal: Stockholders approved a proposal to adjourn the meeting to solicit additional proxies if necessary. However, this proposal became moot as the Issuance Proposal was approved.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies were disclosed beyond the procedural necessity of obtaining stockholder approval for the share issuance to maintain Nasdaq compliance.
Important Facts for Investors
- Voting Results: The Issuance Proposal passed with 24,098,218 votes for, 444,639 against, and 33,281 abstentions.
- Share Count: As of the record date (February 18, 2025), there were 37,025,331 shares of Common Stock outstanding.
- Preferred Stock: There were 44,894 shares of Series A Convertible Preferred Stock outstanding, representing 6,056,284 votes on an as-converted basis for the Adjournment Proposal.
- Regulatory Compliance: The approval enables the company to issue shares in excess of the 19.99% threshold under Nasdaq Listing Rule 5635(d).